Class Action Lawsuit Against Altimmune, Inc.
In response to the considerable losses experienced by investors in Altimmune, Inc. (ALT), legal firm Levi & Korsinsky, LLP has announced a class action lawsuit. This action aims to represent shareholders who were impacted by the company's alleged securities fraud during a specific period.
What Led to the Class Action?
The lawsuit asserts that between August 10, 2023 and June 25, 2025, Altimmune misrepresented its financial health and failed to disclose significant information that could impact investor decisions. The situation escalated after a press release on June 26, 2025, revealed disappointing results from the Phase 2b MASH trial of its product, Pemvidutide. Despite earlier proclamations of success, the actual outcomes indicated a lack of statistical significance in crucial endpoints.
Details of the Phase 2b MASH Trial Results
The results from the trial were not only disappointing but also marked a serious blow to the company’s credibility. Investors were led to believe that significant advancements had been made regarding the treatment of MASH, but reality surfaced when the results did not meet the anticipated statistical significance. The price of Altimmune's stock took a nosedive, dropping by over 53% from $7.71 to $3.61 on the day following these announcements.
Understanding the Class Definition
The class action aims to recover losses for shareholders who suffered during the period in question—August 10, 2023 to June 25, 2025. Those who believe they were affected are encouraged to consider their options. Interested parties need to act promptly, as the deadline to claim a lead plaintiff role is fast approaching.
Next Steps for Investors
Shareholders who experienced financial loss from Altimmune during this timeframe should reach out to Levi & Korsinsky to explore their eligibility for compensation. A key detail is that participation in the lawsuit comes at no out-of-pocket cost to investors. Individuals can claim their rights under the class action without any financial obligation.
Levi & Korsinsky: A Trusted Partner
The firm boasts two decades of experience in securities litigation and has successfully secured substantial compensations for aggrieved shareholders. With a dedicated team of over 70 professionals, the firm is well-regarded within the sector, consistently appearing among the top ranking firms in securities litigation.
Contact Information
For potential class members, direct contact details are as follows:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: jlevi@levikorsinsky.com
Phone: (212) 363-7500
Website: www.zlk.com
Frequently Asked Questions
What is the main purpose of the class action lawsuit?
The class action lawsuit is designed to recover losses for investors affected by alleged securities fraud by Altimmune, Inc.
Who can join this class action?
Investors who incurred losses between August 10, 2023 and June 25, 2025, can join the class action.
Are there any costs involved for investors?
No, involved investors can participate in the class action without incurring any costs or fees.
What should I do if I want to participate?
Contact Levi & Korsinsky to discuss your options and eligibility before the deadline.
When do I need to act by?
The deadline to apply to be a lead plaintiff is October 6, 2025.
